Case of De Novo Nail Psoriasis Triggered by the Second Dose of Pfizer-BioNTech BNT162b2 COVID-19 Messenger RNA Vaccine

A 76-year-old woman developed de novo nail psoriasis after receiving the second dose of the Pfizer-BioNTech BNT162b2 COVID-19 mRNA vaccine. Her symptoms included severe onycholysis and nail sensitivity, which appeared 7 days post-vaccination. The diagnosis was supported by clinical examination and histopathologic findings. Treatment with clobetasol ointment led to significant improvement. This case highlighted a potential triggering effect of the vaccine on psoriasis, although such reactions were rare and should not deter vaccination efforts. The study suggested that immune responses, rather than direct viral infection, might cause dermatologic findings associated with both SARS-CoV-2 infection and vaccination.